68 ML Tecartus 1471000 CELLS/ML Injection

RxCUI: 2572005
RxNorm name: 68 ML Tecartus 1471000 CELLS/ML Injection
Display name: 68 ML Tecartus 1471000 CELLS/ML Injection
Full name: 68 ML Tecartus 1471000 CELLS/ML Injection
Term type: SY
Status: DailyMed mapping
Updated: 2026-06-04 23:39:11

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLA	Proprietary name	Proper name	License type	Status	Latest source
125703	Tecartus	Brexucabtagene Autoleucel	351(a)	Rx	2026-09-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
TECARTUS	BREXUCABTAGENE AUTOLEUCEL	Kite Pharma, Inc.	a16108c2-7ca7-45af-965e-54bda4713022	2026-06-16	Boxed warning, Warnings, Adverse reactions	Exact identifier rxcui: 2572005

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set ID	RxNorm mappings	Terms	SPL version	Label	Effective
a16108c2-7ca7-45af-965e-54bda4713022	Tecartus 100,000,000 CELLS in 68 ML Injection [PSN] · 68 ML brexucabtagene autoleucel 1471000 CELLS/ML Injection [Tecartus] [SBD] · 68 ML Tecartus 1471000 CELLS/ML Injection [SY] · Tecartus 100,000,000 CELLS per 68 ML Injection [SY]	4	16	These highlights do not include all the information needed to use TECARTUS safely and effectively. See full prescribing information for TECARTUS. TECARTUS ® (brexucabtagene autoleucel) suspension for intravenous infusion Initial U.S. Approval: 2020	20260401